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AIM OF THE STUDY 
 
The present study is undertaken: 
1) To study the role of Pap smear in HIV positive women attending      Coimbatore 
Medical College Hospital. 
2) To detect opportunistic infections, cervical dysplasia and cancer cervix in HIV 
positive women. 
3) To increase the awareness of the value of Pap smear as an integral part of 
preventive care for HIV infected women.      
 
INTRODUCTION 
 
HIV/AIDS pandemic is emerging as one of the most serious health problems of 
this century and the focus is shifting fast from developed nations to developing 
countries including India due to its vast population1. 
In India, around 22% of total reported AIDS cases and 30% of newer HIV 
infections are among women2. HIV infection results in progressive depletion of 
immune system making the host susceptible to various opportunistic infections and 
other AIDS related malignancies. 
Though the process cannot be stopped, it can be slowed down, which would 
improve the quality of life. 
Vulvo vaginal candidiasis , Cervical dysplasia ,Cervical cancer in situ and Pelvic 
inflammatory disease(PID) were added to the revised classification system  of HIV 
infection under category B3. 
Also cervical cancer has an increased occurrence and aggressiveness in HIV 
infected   women. In 1993, The Center for Disease Control and Prevention (CDC) 
added Cervical Cancer to the list of AIDS defining malignancies 4. 
It is very important for the HIV - positive women to have regular Pap smear. Pap 
smear is one of the important screening procedures which  
was introduced by Dr George Papanicolaou and Traut in 1943 to lower the 
morbidity and mortality of cervical cancer by its early detection5. An abnormal pap 
smear can indicate inflammation, infection, dysplasia or cancer6. 
HIV infected women are 10 times more likely to have abnormal pap smears than 
HIV negative women7. Hence CDC recommends, all HIV positive women should 
have a complete gynecological examination, including a pap smear, when they are 
first diagnosed or when they first seek prenatal care8 .Unlike most other cancers, 
Carcinoma Cervix is highly preventable when precursor lesions are detected and 
treated before they develop into cancer9. 
This study is undertaken to mainly highlight the importance of cervical cytology in 
HIV positive women and to increase the awareness about the value of Pap smear as 
an integral part of preventive care for HIV infected women.       
 
REVIEW OF LITERATURE 
India has a population of one billion, around half of whom are adults in the 
sexually active age group. The first AIDS case in INDIA was detected in 1986 
and since then HIV infection has been reported in all states and union 
territories10. 
The spread of HIV in India has been uneven. HIV epidemics are more severe in 
the southern half of the country and the far north-east. The highest HIV 
prevalence rates are found in Andhra Pradesh, Maharashtra, Tamil Nadu and 
Karnataka in the south; and Manipur and Nagaland in the north-east11. 
In the southern states, HIV is primarily spread through heterosexual contact. 
Infections in the north-east are mainly found amongst injecting drug users and 
sex workers12. 
Estimated number of people living with HIV/AIDS, 200713 
People living with HIV/AIDS 2.31 million 
Adult (15 years or above) HIV prevalence 0.34% 
 It is now thought that around 2.3 million people in India are living with HIV. 
Of these, an estimated 39% are female and 3.5% are children. 
 
 
Women and the Biology of HIV Transmission 
The majority of HIV infections are transmitted sexually and so most of the 
transmission occurs through the genital or reproductive systems of men and 
women14. 
The female genital tract 
The female genital tract includes the vagina, cervix, uterus, fallopian tubes and 
ovaries. 
 
 
 
 
 
 
Most HIV transmission in women happens through the vagina, the cervix and, 
possibly, the uterus. 
The risk of transmitting HIV from men to women is much higher than from 
women to men. This is in part because of the much larger surface area of the 
vagina and cervix .Women are exposed to considerable amounts of seminal 
fluid during sex, if ejaculation occurs15. 
The vagina is particularly vulnerable to invasion by bacteria, viruses and other 
germs. It is an ideal place for bacteria to grow, as it is warm and moist. It also 
provides an easy entry into the body. 
Women with low levels of the hormone estrogen may be at increased risk for 
transmission of HIV because low estrogen levels directly affect the vaginal 
wall, making it thinner and accessible for easy passage of HIV through the 
wall16. 
Routes of HIV entry through the female genital tract: 17 
The vagina has various defense mechanisms against infection. The walls of the 
vagina are made up of mucous membrane that is thicker than the mucous 
membrane in other places where HIV transmission often happens, such as the 
rectum or cervix .The walls of the vagina have ten to twelve overlapping layers 
of epithelial cells, which create a strong barrier against germs such as viruses 
and bacteria. The vagina is also a home for Lactobacilli which are thought to 
give some protection against other bacteria and viruses that might infect the 
body. 
It was thought that HIV can only get through the walls of the vagina through 
small tears or sores in the mucous membrane. Recent research suggests that 
HIV can pass between or through healthy cells. This means that HIV can still 
infect women even if the vaginal mucous membranes are healthy and intact. 
Unlike the vagina, the mucous membranes lining the cervix and uterine walls 
have only a very thin layer of cells and so it is much easier for viruses like HIV 
to cross into the body through the cervix and possibly the uterus.  
Because the cervix acts as a barrier to protect, it is a home for a large number of 
immune cells. Many of these immune cells are CD4+ cells, which are the most 
vulnerable to HIV. 
Factors altering woman’s susceptibility to HIV: 
Hormonal changes:  
 Studies have suggested that the lining of the vagina gets thinner closer to 
menstruation than during other periods of a woman’s cycle. This suggests that 
the risk of HIV infection over the course of menstrual cycle may vary. 
Bacterial vaginosis: 
Changes in the vaginal bacterial flora have been found to increase a woman’s 
risk of HIV infection by as much as 2.5 times. This alteration in the vaginal 
bacteria is referred to as altered vaginal flora (AVF) or bacterial vaginosis (BV) 
18. 
Age: Young women, particularly below the age of 24, appear to be much more 
vulnerable to HIV. This is because their genital tracts are not mature and may be 
more prone to tears and abrasions during sexual intercourse. Women who have 
gone through menopause are also at a higher risk of HIV infection, because the 
lining of the uterus becomes thinner and the vagina becomes drier.  
Immature cervix (cervical ectopy): Up until the age of 18, a woman’s cervix 
is still developing. During this time, the thinner cells that line the cervix are 
found further down into the vagina than they are in older women. This is called 
“cervical ectopy” or an “immature cervix”. Since the cells lining the cervix 
provide a thinner and weaker barrier to HIV, young women with cervical ectopy 
have a much greater risk of HIV infection.  
Pregnancy: Some researchers have found that pregnant women may be more at 
risk for HIV because of immunological and hormonal changes. 
Sexually transmitted infections and HIV: 19 
Women are at more risk for sexually transmitted infections (STIs) than men. In 
addition, women often have fewer obvious symptoms, and therefore do not get 
treatment until the infection has been present for a long time. Having an STI 
increases the risk of HIV transmission in several ways. 
All STIs cause inflammation of the mucous membrane. Inflammation is the 
body’s immune response to an infection or irritation. When the mucous 
membrane is inflamed, a large number of immune cells are recruited to fight the 
infection.  
Many of those immune cells will be CD4+ cells or other immune cells that are 
involved in HIV transmission. In addition, when cells are fighting off an 
infection, they become activated. Activated CD4+ cells are more easily infected 
by HIV. Some STIs also cause open lesions or sores, which offer an easy way 
for the virus to get into the body and cause an infection.  
Gynecological problems in HIV: 
Gynecologic problems are common among HIV-positive women and are 
frequently present at the time of initial presentation for evaluation and care.  
Minkoff et al. found that 46.9% of 262 HIV-infected women had  atleast one 
incident gynecologic condition with serial assessment (Minkoff, 1999)20.  In a 
study of women admitted to an inpatient AIDS service, although only 9% were 
admitted with a primary gynecologic problem, 83% had coexisting gynecologic 
disease when evaluated (Frankel, 1997)21. 
Some gynecologic issues are unrelated to the patient’s serologic status, whereas 
others are directly related to HIV disease and associated immune suppression. 
Still others are associated epidemiologically with HIV because of common risk 
factors, such as sexual behavior or substance abuse. 
 HIV infection primarily affects women during their reproductive years, 
gynecologic and reproductive health care will play an increasingly important 
role in the overall care of the HIV-infected woman. With improved longevity 
and quality of life, gynecologic problems may be encountered more commonly 
or may be more prominent.  
The Center for Disease Control and Prevention (CDC) added invasive cervical 
cancer to its list of AIDS-defining conditions in 1993. Still, much remains 
unknown about the incidence and natural history of this disease in HIV-positive 
women. 
 Pap smear screening of HIV positive women has demonstrated a four- to 
tenfold elevation in abnormal results compared to HIV negative women.  
It is hoped that such screening appreciably decreases the potential for cervical 
cancer in HIV positive women.  
Over the past ten years, a great deal of research has amassed regarding Pap 
smear findings and their management in HIV positive women. 
In the setting of HIV infection 30–60% of Pap smears exhibit cytologic 
abnormalities and 15–40% have evidence of dysplasia; these rates are 10–11 
times greater than those observed among HIV negative women 
(Maiman,1998)22. 
Malignancy in cervix is believed to begin to develop in adolescents or young 
adults and progress slowly over the decades. (Winkelstein,1990; Feldman, 
1997).  
HIV AND CERVICAL DYSPLASIA 
Abnormal cervical cytology is more common among HIV-infected women and 
is associated with the presence of HPV infection and the degree of immune 
suppression.  
Both frequency and severity of abnormal Pap smears and histologically 
documented dysplasia increase with declining CD4 counts and have also been 
associated with higher HIV-RNA levels (Garzetti, 1995; Shah, 1996; Davis, 
2001)23,24,25 
Incidence of abnormal Pap smears is increased in HIV-infected as compared to -
uninfected women, and is associated with lower CD4 counts; progression and 
regression of Pap smear abnormalities have been associated with level of 
immune suppression and plasma viremia  as reflected in CD4 count and HIV 
viral load (Massad, 2001; Schuman, 2003)26,27 
 Increased HPV viral load, seen in women with more advanced HIV, is also 
associated with increased frequency, severity, and incidence of cervical 
dysplasia (Heard, 2000;Weissenborn 2003; Cohn, 2001)28,29,30 
In HIV-positive women dysplasia is associated with more extensive cervical 
involvement and is more likely to involve other sites in the lower genital tract, 
such as the vagina, vulva, and perianal region (Hillemanns, 1996; Korn, 1995; 
Maiman, 1990; Petry, 1996; Williams, 1994)31,32,33,34,35 as compared with HIV-
negative women.  
Recent studies have shown increased incidence of oncogenic HPV types 
(Minkoff, 1998) and increased incidence of biopsy-proven cervical dysplasia 
(Ellerbrock, 2000)36 in HIV-positive women compared with HIV-negative 
controls.  
A French study found an increased likelihood of progression of cervical 
abnormalities in HIV-positive women, although analysis was based on Pap 
Smear results only (Six, 1998)37 
A recent study also found an association between progression of abnormal Pap 
smears and high plasma HIV RNA levels (>100,000 c/ml) (Sewell, 
2000)38.Presently there is little evidence for increased rates of progression to 
invasive cancer, particularly if adequate screening and treatment programs are 
in place. 
INVASIVE CERVICAL CANCER IN HIV DISEASE: 
 In 1990, Maiman and colleagues evaluated 37 women diagnosed with invasive 
cervical cancer. Nineteen percent of the cancer patients under age 50 were   HIV 
positive.  
HIV positive patients had more advanced invasive disease than negative ones, 
and disease persisted or recurred in all positive patients compared to 37% of 
negative patients. Other researchers(Relliman, 1990; Schwartz, 1991; Maiman, 
1993) 39,40 have published case reports of rapidly progressive invasive cervical 
cancer in women with HIV.  
Maiman and his colleagues have continued to study the relationship between 
HIV and cervical cancer in a large cohort of women in Brooklyn, where there is 
a high female HIV rate. In this cohort, women with HIV infection and cervical 
cancer have a higher recurrence rate than HIV-negative women diagnosed at 
comparable stages of cancer (Maiman,1993). The HIV positive women had 
increased rates of severe dysplasia, larger lesions, and greater "field effect" than 
the women testing negative (Fruchte , 1997).  
 In a retrospective review of data on cervical cancer and AIDS in women 
registered through the New York City Department of Health and Institutional 
Tumor Registries from 1987 to 1995, Maiman (1997) found a strong correlation 
between cervical cancer and HIV disease throughout New York City.  
The Gynecologic Oncology Group has recently begun a nationwide study (GOG 
154) examining the issue of HIV testing and follow up for women younger than 
50 with invasive cervical cancer. It is hoped that this will provide some insight 
concerning various clinical, pathologic, epidemiologic and demographic factors.   
Oncogenic HPV types play a central role in the relationship between HIV and 
cervical cancer. 
Biomedical research into the interaction between HIV and HPV in laboratory 
cell lines also was described (Cage, 1997). In the lab, HPV infected cells 
display an increased growth response when exposed to interleukin-6 (IL-6), 
tumor necrosis factor (TNF-α), and the HIV-produced tat protein. Since HIV 
can up-regulate the production of IL-6 and TNF-α, there are several possible 
pathways by which HIV in the genital tract may enhance the growth potential 
for HPV infected cells, conceivably leading to an increased risk of cervical 
cancer.  
Recent African data found that without high-risk HPV present, the risk ratio for 
cervical cancer between HIV-positive and HIV-negative women was 
approximately 1 (Hawes, 2003)41.  
Although there is little evidence that HIV infection is having a large effect on 
cervical cancer rates, linking of US AIDS and cancer registries has found that 
observed cervical cancer cases in HIV-infected women are up to 9-fold higher 
than the expected number of cases; however, the likelihood of cervical cancer 
was not related to CD4 count (Mbulaiteye , 2003)42.  
In an analysis of women in the HER study, the rate of invasive cervical cancer 
was 1.20/1000 person-years in HIV-infected women as compared to 0/1000 
person-years in high-risk HIV-negative women (Phelps, 2001)43.  
Mean CD4 cell count was 443 cells/ mm3 at time of diagnosis of cervical 
cancer in women with HIV. Women with HIV and cervical cancer tend to be 
younger and less immune suppressed compared with HIV-positive women with 
other AIDS-defining conditions. Women with HIV and cervical cancer tend to 
be younger than HIV-negative women with cervical cancer (Lomalisa , 2000)44.  
A prospective cohort study from Italy found that the incidence of invasive 
cervical cancer as a first AIDS-defining condition continued to increase after the 
introduction of HAART, possibly due to the decrease seen in incidence of other 
AIDS-defining diseases after HAART (Dorrucci, 2001)45.  
HIV-positive women with invasive cervical cancer appear to present at more 
advanced stages (especially with CD4 < 200/ mm3), may metastasize to unusual 
locations , have poorer responses to standard therapy, and have higher 
recurrences and death rates, as well as shorter intervals to recurrence or death, 
compared with HIV-negative women of similar stage (Klevens, 1996; Maiman, 
1990)46.  
 Screening methods: 
1. Cervical exfoliative cytology47 (conventional Pap smear): 
 Exfoliative cervico vaginal cytology has been regarded as the gold standard for 
cervical screening programs. Pap smear is widely recognized as the most cost 
effective cancer screening test devised and serves as a model for screening of 
other malignancies. Pap smear is one of the important screening procedures 
which was introduced by Dr George Papanicolaou and Traut in 1943 to lower 
the morbidity and mortality of cervical cancer by its early detection.  
Due to mass screening tests by Pap smear, the incidence of invasive carcinoma 
is grossly reduced. The availability of cervical cytology to screen for cervical 
cancer often permits diagnosis at the pre invasive stage, when treatment can 
almost always prevent progression to invasive cancer. For this reason, screening 
for cervical cancer is important in all women.  
Screening for cervical cancer is of particular concern to HIV infected women 
and adolescents since the incidence of cervical intraepithelial neoplasia (CIN) 
and cancer cervix are four to five times higher in HIV-positive women and 
adolescents compared to HIV-negative women and adolescents with high risk 
sexual behavior .In the setting of HIV infection , 30–60% of Pap smears exhibit 
cytologic abnormalities and 15–40% have evidence of dysplasia; these rates are 
10–11 times greater than those observed among HIV-negative women 
(Maiman,1998). 
2) Schiller’s iodine48: 
In 1929 Schiller described this method. The normal cervical and vaginal 
epithelium rich in glycogen take up dark brown stain with iodine. Rapidly 
proliferating cells utilize all the glycogen and hence are deficient in glycogen. 
They remain unstained. Hence, iodine negative areas are considered as 
abnormal. 
3) Visual inspection of the cervix with acetic acid48 (VIA): 
The technique is very simple and consists of examination of the cervix two 
minutes after 4% acetic acid application .Lesions which are stained acetowhite 
are regarded as positive. 
 
4) Speculoscopy 48: 
Speculoscopy involves inspection of cervix following the application of 5% 
acetic acid with chemiluminiscent  light and a low power magnification. 
5) Cervicography 48: 
Cervicography involves taking photographs of the cervix using a special camera 
following the application of 5% acetic acid during a routine pelvic examination 
and pap smear collection. The photographs are then developed and the slide is 
projected on a 2×2 meter screen and read by an expert in colposcopy. 
6) Colposcopic examination and biopsy 49: 
Colposcope was invented by Hinselman in 1954. Colposcope is inspection of 
lower genital tract under relatively low stereoscopic magnification and bright 
illumination. Topography, surface contour, vascular pattern, colour of cervix are 
all observed. Colposcopy is used to determine the exact distribution and extent 
of lesion, to select the site for direct biopsy, to confirm the cytological findings 
and to rule out  invasive carcinoma. 
RECOMMENDATIONS FOR PAP SMEAR SCREENING  
US Public Health Service (USPHS)/Infectious Diseases Society of America 
(IDSA) 2001  
HIV-infected women should have a complete gynecologic evaluation, including 
a pap smear and pelvic exam, as part of their initial evaluation. A Pap smear 
should be obtained twice in the first year after diagnosis of HIV infection. If 
these results are normal, annual examinations are then indicated.  
More frequent Pap smears should be considered:  
o with previous abnormal pap smear 
o with HPV infection  
o after treatment for cervical dysplasia in women with symptomatic 
HIV infection (including CD4 counts <200/mm3 
Table: Pap Smear Report for Bethesda System50 
 
 
 
 
Specimen adequacy • Satisfactory for evaluation (note presence/absence 
of endocervical transformation zone component)  
• Unsatisfactory for evaluation (specify reason)  
General 
categorization  
• Negative for intraepithelial lesion or malignancy  
• Epithelial cell abnormality  
• Other  
Interpretation/result • Negative for intraepithelial lesion or malignancy  
o infections  
o reactive changes (inflammation, radiation)  
o atrophy  
• Epithelial cell abnormalities  
o atypical squamous cells (ASC)  
 of undetermined significance (ASC-
US)  
 cannot exclude HSIL (ASC-H)  
o low-grade squamous intraepithelial lesion, 
including HPV changes and mild dysplasia 
CIN1  
o high-grade squamous intraepithelial lesion, 
including moderate and severe dysplasia, 
CIN2, CIN3  
o squamous cell carcinoma  
o glandular cell abnormalities  
• Other  
o endometrial cells in a woman greater than or 
equal to 40 years of age  
Table : Recommended Management for Abnormal Pap Smears 
 PAP SMEAR RESULT         MANAGEMENT 
Unsatisfactory Repeat Pap smear 
Partially obscuring- 
inflammation 
Evaluate for infection; consider repeat Pap 
smear 
Epithelial cell abnormality  
- atypical glandular cells Colposcopy, endocervical sampling; 
endometrial sampling if > 35 yrs. or with 
abnormal bleeding; cervical conization if 
initial evaluation negative and cytology 
favors neoplasia 
- atypical squamous cells 
(ASCUS and ASC-H) 
Colposcopy, biopsy if indicated; 
endocervical sampling if unsatisfactory 
colposcopy; follow with Pap every 6 
months, consider repeat colposcopy annually 
if Pap unchanged 
- low-grade squamous 
intraepithelial lesion (LSIL, 
CIN1) 
Colposcopy, biopsy if indicated; 
endocervical sampling if unsatisfactory 
colposcopy; follow with Pap every 6 
months, consider repeat colposcopy annually 
if Pap unchanged 
- high-grade squamous 
intraepithelial lesion (HSIL, 
CIN2-3, carcinoma-in-situ) 
Colposcopy, biopsy, endocervical sampling; 
treat with loop excision or conization 
- invasive carcinoma Colposcopy with biopsy or conization; treat 
confirmed invasive disease with surgery or 
radiation (referral to gynecologic oncologist 
needed) 
 HIV positive women should continue to be followed closely for evidence of 
lower genital tract neoplasia, regardless of antiretroviral therapy or viral load. 
The goal of Pap smear screening is to prevent cervical and/or lower genital tract 
cancer. The Pap smear is a screening test with an average sensitivity of about 
85% and an average specificity of about 98% .It is evident that the sensitivity 
and specificity of the Pap smear do not differ significantly among HIV-positive 
and HIV-negative women. Yet the proportion of HIV-positive women who 
receive abnormal Pap smear results is much higher than for HIV-negative 
women. 
Management of Pap smear findings should rightly be a part of primary care of 
all women. This is based on a thorough review of the available research and 
clinical recommendations and a belief that Pap smear management is not 
outside the scope of primary care for HIV –positive women.  Pap smear is a 
valuable guide for primary care providers and their HIV positive female 
patients.  
Pap smear Screening vs. Colposcopy in HIV: 
Colposcopy involves direct examination of a  woman's cervix with a special 
microscope and has several critical disadvantages. It requires management by a 
specialist and the procedure can be painful. Further, the biopsies that frequently 
accompany the colposcopic examination are invasive and entail a risk of 
bleeding or infection. Also this is not a cost effective way to identify cervical 
cancer in the general population.   
 Indications for Colposcopy: 
 
• Cytologic abnormality (atypia or greater, including ASC, AGC)  
• History of untreated abnormal Pap smear. 
•  periodic colposcopy after treatment of cervical dysplasia  
•  evidence of HPV infection  
• CD4 <200/mm3  
 
 
ASC-atypical squamous cells  
 
AGC, atypical glandular cells  
  
 
 
New Technologies under Investigation 
 These technologies are intended to reduce the false-negative rate, improve 
sensitivity and specificity of screening as well as the adequacy of the Pap smear 
thereby potentially improving laboratory productivity.  
These new technologies include  
• methods to improve the quality and adequacy of the Pap smear (liquid-
based/thin-layer preparations) 
• methods to improve Pap smear interpretation (computer-assisted 
screening) 
• testing for the presence of high-risk human papilloma virus (HPV).  
LIQUID-BASED/THIN-LAYER PREPARATIONS 
 (ThinPrep and Auto Cyte Preparation) 51,52 
The Pap smear is obtained with either a cytobrush and Ayre spatula or a cervical 
“broom” device. The clinician does not smear the sample directly onto a glass 
slide. Instead, the sample is placed in a small bottle containing fixative solution. 
The sample is sent to the cytology laboratory where it is filtered or centrifuged 
to remove excess blood and debris. The cells are then transferred to the slide in 
a “mono” layer. The slide is stained and examined manually in the conventional 
way. 
Advantages of the liquid-based technique include improved transfer of cells 
from the collection device and uniformity of the cell population in each sample. 
This method provides representative residual material in collection media that 
can be used for additional adjunctive testing (e.g., HPV testing). 
COMPUTER-ASSISTED SCREENING 
(AutoPap and AutoCyte Screen) 53,54 
With AutoPap, the device reviews the material on the slide and, based on an 
algorithm, “scores” the slide as to the likelihood of an abnormality being 
present. This algorithm includes a variety of visual characteristics, such as shape 
and optical density of the cells. The device typically does not show the 
cytotechnologist which of the cells are likely to be abnormal. 
The AutoCyte Screen device presents cell images to a human reviewer who 
then determines whether manual review is required. After the human reviewer 
has entered an opinion, the device reveals its determination based on a ranking 
as to whether manual review is warranted. When the human reviewer and the 
computer agree that no review is needed, a diagnosis of “within normal limits” 
is given. Manual review is required for any case if designated by either the 
cytologist or the computer ranking. 
 
HPV TESTING 55,56,57 
Hybrid Capture II is the latest refinement of HPV tests and has been described 
as having enhanced sensitivity. It can detect 13 high-risk types of HPV. The 
sample is collected with a cervical swab from the transformation zone and 
placed into transport medium. The test may also be performed from residual 
material collected in liquid-based medium for monolayer preparation. 
 In the laboratory, cellular DNA is denatured and mixed with a ribonucleic acid 
probe that binds only to HPV DNA. The DNA “hybrid” is then captured by 
antibodies coating the sides of the tube. Next, a chemical is added, causing a 
chemoluminescent reaction. The amount of light that is measured can be used to 
determine the presence of HPV and the viral load. 
However, the current evidence indicates that these new tests will increase the 
detection of lesions that may not be clinically meaningful. Specifically, most of 
the lesions detected are borderline or low-grade abnormalities. Unless new 
technology becomes cost effective, its application and utility will be limited.   
Women who already have problems of access to the health care system are 
likely to face another burden that may further decrease their opportunity for 
screening.  Providing better access to regular screening and consistent follow-up 
of patients with abnormal results is likely to have greater value than the 
implementation of new technology.  
DISCUSSION 
 Invasive cervical cancer is an AIDS defining malignancy. Human uterine cervix is 
unique in that it is the site of an epithelial neoplasm occurring with high prevalence 
rate that is accessible, easily detectable, amenable to long term study with little 
discomfort and relative safety to patient.  
The recognition of the cancer cervix in a truly early stage is one of the recent 
advances in the effort to control the disease. 
Pap smear abnormalities in HIV infected women: 
In the present study 45% of women had abnormal Pap smear, which included 
inflammation 14%, reactive atypia6%, various organisms 20% and epithelial 
abnormalities 5%. 
This correlates with the study of Byrne et al (1989) who had reported abnormal 
Pap smears in 37% of HIV positive women. 
Also it is similar to the observations made by Maiman et al (1998), who found that 
30–60% of Pap smears exhibit cytological abnormalities and 15–40% have 
evidence of dysplasia. 
The incidence of abnormal Pap smears for the HIV positive women in another 
study was 63%. (Provencher,1988) 
 
TABLE 17: COMPARATIVE ANALYSIS OF PAP SMEAR 
ABNORMALITIES IN HIV INFECTED WOMEN. 
S. No Pap smear 
findings 
Present 
Study 
Byrne 
et al 
Maiman 
et al 
Provencher 
et al 
1 Normal 55% 63% 40-70% 37% 
2 Abnormal 45% 37% 30-60% 63% 
Incidence of abnormal Pap smears was increased in HIV-infected women, and was 
associated with lower CD4 counts; progression and regression of Pap smear 
abnormalities had been associated with the level of immune suppression , as 
reflected in CD4 count ( Massad , 2001; Schuman, 2003). 
These results indicate that HIV infected women are more likely to have abnormal 
pap smears than HIV negative women. 
HIV and gynecological problems: 
In the present study 65% women had gynecological problems. Vaginal discharge 
was the most common presenting symptom (51%). 
Minkoff et al (1999), had a similar observation in which 46.9% of 262 HIV 
infected women had at least one gynecological problems with serial assessment.  
But this is less than the observations made by Frankel et al (1997) ,in which 83% 
of HIV positive women had gynecological problems when evaluated (Frankel, 
1997).  
These results indicate that gynecologic problems are common among HIV-positive 
women and are frequently present at the time of initial presentation for evaluation 
and care.  
Age and Cervical cancer in HIV infected women: 
In the present study, maximum incidence of epithelial abnormalities was between 
ages of 31-40 years. Both the patients with squamous cell carcinoma were under 
the age of 40 years. 
This observation was similar to that of Lomalisa et al, (2000), who found that in 
HIV positive women cervical cancer presented between the ages of 35 and 40, 
which is 10-15 years earlier than expected in HIV negative women.  
Malignancy in cervix is believed to begin to develop in adolescents or young adults 
and progress slowly over the decades. (Winkelstein, 1990; Feldman,1997).  
In 1990, Maiman and colleagues evaluated 37 women diagnosed with invasive 
cervical cancer. Nineteen percent of the cancer patients under age 50 were   HIV-
positive. 
These results showed that women with HIV and cervical cancer tend to be younger 
than HIV-negative women with cervical cancer. 
CD4 count and epithelial abnormalities: 
In the present study, maximum women with epithelial abnormalities had CD count 
between200-500. Two of them had SCC and one of them had LSIL. Mean CD4 
count of women with epithelial abnormalities was 297.8 and mean CD4 count of 
women with SCC was 422.5.  
This was similar to that of Lomalisa et al,(2000) who found that mean CD4 cell 
count was 443 cells/ mm3 at time of diagnosis of cervical cancer in women with 
HIV.  
Both frequency and severity of abnormal Pap smears and histologically 
documented dysplasia increase with declining CD4 counts. (Garzetti, 1995; Shah, 
1996; Davis, 2001).  
But it was in contrast with the study of  Mbulaiteye et al , (2003) who found that 
cervical cancer was not related to CD4 count . 
HIV and HPV co infection in epithelial abnormalities: 
In the present study one woman had HPV related LSIL, whose CD4 count was 
131. 
This observation was similar to the following studies. Women infected with both 
HIV and high risk HPV had a more than 40 fold higher risk of squamous intra 
epithelial lesions (SIL) than HIV non infected women (Moodely et al, 2006) 
Sun et al. (Sun, 1995) have suggested that the presence of immune suppression 
shifts the ratio of latent: clinically expressed HPV infections from 8:1 in the 
general population to 3:1 in HIV-positive women with CD4 >500/mm3 to 1:1 in 
HIV-positive women with CD4 <200/mm3.  
In HIV-positive women the prevalence and persistence of HPV infection increases 
with decreasing CD4 count and increasing HIV RNA levels (Palefsky,1999) and 
studies showed that oncogenic HPV types were more common with lower CD4 
counts and/or higher viral loads(Luque 1999; Minkoff,1998). Higher HPV viral 
loads are also associated with lower CD4 counts (Heard, 2000). 
Cross-sectional and longitudinal samples of HIV positive women demonstrated 
that both rates of HPV infection and disease and of high-grade dysplasia increase 
as CD4 counts lower (Schafer, 1991; Vermund, 1991; Anastos, 1992; Wright, 
1994) 
These results indicate that oncogenic HPV types play a central role in the 
relationship between HIV and cervical cancer. 
Incidence of various organisms and HIV: 
In the present study 8% women had shift in flora (BV), 7% had candida and 4% 
had herpes virus. Maximum no of women with organisms had CD4 count less than 
500.Mean CD4 count of shift in flora - 387.57, candida - 385, herpes virus-313.2.  
In one comparative study 34% of HIV positive women had candidiasis, herpes -
11% and shift in flora 5 % (Archana Sharma, Y.S.Marfatia, Megha Modi -2009) 
18–42% prevalence among HIV-infected women; BV is more prevalent and 
persistent as compared with HIV-negative controls and prevalence, persistence and 
severity increase with lower CD4 counts (Cu-Uvin, 1999; Greenblatt, 1999; 
Jamieson, 2001). 
Studies suggest that BV or BV-associated organisms may enhance HIV 
transmission (Martin, 1999; Olinger, 1999).  
BV has been associated with increased HIV expression in the genital tract (Cu-
Uvin, 2001).  
Analysis from the HER Study found that vulvovaginal candidiasis occurred with 
higher incidence and greater persistence, but not greater severity, among HIV-
infected as compared to high-risk HIV-uninfected women. 
 Lower CD4 count was associated with vulvovaginal candidiasis (Cu-Uvin 
1999;Duerr, 2003). 
Incidence of Trichomoniasis in HIV-positive women 10–17% (Minkoff, 1999; 
Sorvillo, 1998).  
Studies have not shown increased prevalence, incidence, persistence or recurrence 
compared with HIV-negative women or with lower CD4 counts (Cu-Uvin, 2002).  
 
MATERIAL AND METHODS 
 
This analytical study was carried out in the department of pathology, Coimbatore 
Medical College during the period of December 2008 to April 2010.Ethical 
clearance was obtained from institutution’s ethics committee. 
 One Hundred HIV positive women attending STD/ Gynecology O.P were 
included in this study, after getting informed consent. Strict confidentiality was 
maintained throughout the study. 
The age group varied from 20 years to 50years.A detailed history of the patient 
was obtained. General examination and pelvic examination were performed. Per 
speculum examination was performed to assess cervix. The patient was placed in 
lithotomy position. The Ayre’s spatula was  introduced through the external os and 
the squamo columnar  junction was scraped by rotating the spatula to 360˚.The 
scraping was then evenly  spread on to a glass slide which was immediately fixed 
using  95% isopropyl alcohol and proceeded with Papanicolaou staining. The 
slides were read and analyzed according to the Bethesda 2001 reporting guidelines. 
 
Papanicolau’s Staining Procedure: 58,59,60,61 
The three main advantages of this staining procedure are: 
1) Good definition of nuclear detail. 
2) Cytoplasmic transparency. 
3) Indication of cellular differentiation of squamous epithelium. 
Because of these qualities, the method has wide applications, especially in cancer 
and hormonal cytology. 
It is a polychrome staining method which depends on degree of cellular maturity 
and cellular metabolic activity. 
There are four main steps in the staining procedure: 
1) Fixation. 
2) Nuclear staining. 
3) Cytoplasmic staining. 
4) Clearing. 
Reagents: 
1) Harris’ Hematoxylin: 
2) OG 6: 
Orange G - 0.5 (or) 1% solution in 95% alcohol               100ml                 
Phosphotungstic acid                                                         0.015 gm                  
 3)  EA 36: (Eosin Alcohol) 
Light green SF yellowish   - 0.14% in 95% alcohol            45 ml 
Bismarck brown Y-0.5% in 95% alcohol                  10ml 
Eosin Yellowish -0.55% in 95% alcohol                   45 ml 
Phosphotungstic acid                                                    0.2 gm 
Lithium carbonate, saturated aqueous solution          1drop 
Fixation: 
The cell samples are smears and must be well fixed in 95% isopropyl alcohol. 
Nuclear staining: 
The Hematoxylin nuclear stain is a natural stain which has been used for over 100 
years .It has affinity for chromatin, attaching to sulphate groups on the D.N.A 
molecule. 
Harris’ Hematoxylin is commonly used in cytology and has the advantage of being 
usable almost immediately after preparation; where as other types need to mature. 
The regressive stain method gives especially clear contrast. 
 
Cytoplasmic stain: 
Eosin gives pink colour to: 
 (a) Cytoplasm of mature squamous cells. 
 (b) Nucleoli. 
 (c) Cilia. 
Light green stains cytoplasm of metabolically active cells blue: 
       (a) Para basal squamous cells. 
 (b) Intermediate squamous cells. 
  (c) Columnar cells. 
Bismarck brown does not add a characteristic colour to the cytoplasm. 
Phosphotungstic acid has two functions in EA solution: 
As an accentuator and mordant. 
The effects of Orange-G are only evident in smear when keratinised cells are 
present. However it is likely that it enhances red blood cell staining and acts a 
mordant to EA stain. 
Immerse cells in absolute alcohol, to dehydrate completely preparatory to clearing. 
Clearing: 
Clearing in Xylol results in cellular transparency and precedes mounting. Xylol is 
the commonest clearing agent and is miscible with both alcohol and D.P.X 
mountant. 
Xylol is colourless , chemically nonreactive and has almost  the same refractive 
index as glass which is important to give the best possible transparency of the 
image. 
R.I .Xylol   -1.494 
R.I glass   -1.51 
Mounting: 
The mountant          
 1. Acts as a permanent bond between slide and coverslip. 
 2. Protects cell material from air drying and shrinkage. 
 3. Acts as a seal against oxidation and fading of the stain  
 
Observation and Results 
A total of 100 HIV positive women were studied in the period between 
December 2008 to April 2010. 
           TABLE 1: SOCIO DEMOGRAPHIC CHARACTERS  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S. No Variables No of cases 
n=100 
% 
1 Age in years 
  <=30 years 
  31-40 years 
  41-50 years 
 
 
31 
52 
17 
 
 
31% 
52% 
17% 
 
2 Socio-economic status 
Low 
Middle 
Higher 
 
24 
74 
2 
 
24% 
74% 
2% 
3 Age at time of marriage 
<20 years 
20-30 years 
>30 years 
 
52 
46 
2 
 
52% 
46% 
2% 
4 Menopausal status 
Pre menopausal 
Post menopausal 
 
97 
3 
 
97% 
3% 
5 Literacy 
Illiterate 
<5th std 
 5th -12th std 
Graduate 
 
28 
15 
53 
4 
 
28% 
15% 
53% 
4% 
In the present study, 52% of women were from the age group of 31-40 years. The 
youngest patient was 20 years and the oldest 50 years. 
74% women belonged to middle socio economic status, 24% women were of lower 
economic status, where as only 2% women were of higher socio economic status. 
52% of women were married at the age of 15-19 years. Mean age at marriage was 
20.5 years. Only 2 women were married after 30 years. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 2: RESULTS OF PAP SMEAR 
 
S. No Variables No of cases 
n=100 
% 
1 Negative for intra 
epithelial lesion or 
malignancy(NILM) 
1.Noinflammation          
and epithelial 
abnormality 
2. Inflammation 
3.Reactive cellular 
changes 
4 Organisms: 
a. Shift in flora 
b. Candida 
c.  Herpes simplex 
virus 
d. Trichomonas 
vaginalis 
5. Atrophic smears       
95 
 
 
52 
 
 
14 
6 
 
 
8 
7 
4 
 
1 
 
            3 
95% 
 
 
52% 
 
 
14% 
6% 
 
 
8% 
7% 
4% 
 
1% 
 
        3% 
2 Epithelial 
abnormalities 
         LSIL 
         SCC 
 
 
3 
2 
 
 
3% 
2% 
 
55% of women had normal Pap smear and 45% had abnormal Pap smear. 
Inflammation was present in 14% of women. Reactive cellular changes were 
present in 6% women. Organisms were present in 20% women. LSIL was present 
in 3% of women and SCC was present in 2% women 
TABLE 3: RELATIONSHIP BETWEEN AGE AND PAP SMEAR 
FINDINGS 
S. No Age in 
years 
Pap Smear findings 
Normal       
(n=55) 
Abnormal      
(n=45) 
Total     
(n=100) 
1 <=30 16(51.6%) 15(48.4%) 31 
2 31-40 27(51.9%) 25(48.1%) 52 
3 41-50 12(70.6%) 5(29.4%) 17 
 
Maximum incidence of abnormal Pap smear was between 31-40 years. Only 29.4% 
0f women between 41-50 years had abnormal Pap smear. 
         Chi-Square Test 
 
Value df Sig.  
2.012(a) 2 .366 
 
P value >0.05, indicates that the relationship between Age and Pap smear findings 
is statistically not significant. Hence it is concluded that Pap smear abnormalities 
could occur irrespective of age group. 
 
 
 TABLE 4: RELATIONSHIP BETWEEN PAP SMEAR AND 
SOCIO ECONOMIC STATUS 
S. No S.E status              Pap smear findings 
Normal       
n=55 
Abnormal        
n=45 
Total       
n=100 
1 Low 13(54.2%) 11(45.8%) 24 
2 Middle 40(54.1%) 34(45.9%) 74 
3 High 2(100%) -   2 
 
45.9% women from middle socio economic status had abnormal Pap smear. None 
of the women from high socio economic status had abnormal Pap smear. 
 
             Chi-Square Test  
 
Value df Sig.  
1.670 2 .434 
 
  P value <0.05; indicates that the relationship between Pap smear and socio 
economic status is statistically not significant. Hence it is concluded that Pap smear 
abnormalities could occur irrespective of socio economic status. 
  
 
TABLE 5: COMPARISON OF AGE AND EPITHELIAL 
ABNORMALITIES 
 
S. No Age in 
years 
Total no of 
women 
n=100 
No of women with epithelial       
abnormalities 
LSIL 
n=3 
SCC 
n=2 
Total 
n=5 
1 <=30 31(31%) - - - 
2 31-40 52(52%) 2(3.85%) 2(3.85%) 4(7.70%)
3 41-50 17(17%) 1(5.88%) - 1(5.88%)
 
Maximum incidence of epithelial abnormalities were between age of  
31-40 years .Two of these had LSIL while the other two had SCC. Only one 
patient was between 41-50 years, who had LSIL. 
 
 
 
 
 
 
TABLE 6: 
COMPARISON OF SOCIO-ECONOMIC STATUS AND EPITHELIAL 
ABNORMALITIES 
 
S. No Socio 
economic 
Status 
Total no of 
women n=100 
No of women with epithelial 
abnormalities 
LSIL 
n=3 
SCC 
n=2 
Total 
n=5 
1 Low 24(24%) 2(8.33%) - 2(8.33%)
2 Middle 74(74%) 1(1.35%) 2(2.70%) 3(4.05%)
3 Higher 2(2%) - - - 
 
All women with epithelial abnormalities were present in lower and middle 
socioeconomic group. None of them were in higher socio economic group. 
 
 
 
 
 
 
 
 
 TABLE 7: 
COMPARISON OF AGE AT MARRIAGE AND EPITHELIAL 
ABNORMALITIES 
 
S. No Age at 
Marriage 
Total no of 
Women 
No of women with epithelial 
abnormalities 
LSIL 
n=3 
SCC 
n=2 
Total 
n=5 
1 <20 52(52%) 2(3.84%) 1(1.92%) 3(5.76%)
2 20-30 46(56%) 1(2.17%) 1(2.17%) 2(4.34%)
3 >30 2(2%) - - - 
 
 
Women with age at marriage <20 years only had maximum epithelial 
abnormalities. None of the women with epithelial abnormalities had age at 
marriage above 30 years. 
 
 
 
 
 
 
 
                                               TABLE 8: 
COMPARISON OF LITERACY AND EPITHELIAL ABNORMALITIES 
S. No Literacy Total no of 
Women 
n=100 
No of  women with epithelial 
abnormalities 
LSIL 
n=3 
SCC      
n=2 
Total    
n=5 
1 Illiterate 28(28%) 1(3.57%) - 1(3.57%) 
2 <5th std 15(15%) - 2(13.33%) 2(13.33%)
3 5-12th std 53(53%) 2(3.77%) - 2(3.77%) 
4 Graduate 4(4%) - - - 
 
Epithelial abnormalities were present in women who studied <5thstd and up to 
12thstd. Only 20% of them were illiterate .None of the graduates had epithelial 
abnormalities. 
 
 
 
 
        
        
TABLE 9: DISTRIBUTION OF PRESENTING COMPLAINT 
S.NO Presenting complaint No of  Cases (n=100)
No % 
1 
 
Discharge per vaginum 55 55% 
2 
 
 
Asymptomatic 35 35% 
 
3 
 
Urinary symptoms 3 3% 
4 
 
Itching 2 2% 
5 
 
Ulcers over genitalia 3 3% 
6 Irregular bleeding 2 2% 
 
 
65% of women had gynecological complaints and 35% of women were 
asymptomatic. Most common presenting complaint was discharge per vaginum 
(55%). 
 
 
 
 
TABLE 10: RELATIONSHIP BETWEEN PRESENTING COMPLAINTS 
AND PAP SMEAR FINDINGS 
S. No Pap smear 
findings 
Presenting  complaints 
Asymptomatic 
n=35 
With 
complaints 
n=65 
Total    
n=100 
1 Normal  32(58.2%) 23(41.8%) 55 
2 Abnormal  3(6.7%) 42(93.3%) 45 
 
93.3% women with gynecological complaints had abnormal Pap smear. But only 
6.7% women with no complaints had abnormal Pap smear. 
Chi-Square test: 
Value Df Sig 
28.871 1 .000 
            
   P<0.01;indicates that the relationship between Presenting complaints and Pap 
smear findings is statistically significant. 
 
 
 
 
 
TABLE 11: FINDINGS ON PER SPECULUM EXAMINATION: 
  
Speculum findings Cases 
No % 
Normal cervix 49 49% 
Erosion cervix 47 47% 
Cervix bleed on touch 2 2% 
Irregular growth cervix 1 1% 
Venereal  warts 1 1% 
 
 
51% of women had abnormal cervix and 49% had normal cervix. Cervical erosion 
was present in 47% patients, cervix bleed on touch in 2% of women. One patient 
had an irregular growth on cervix. 
 
 
 
 
 
 
 
 TABLE 12: RELATIONSHIP BETWEEN PAP SMEAR RESULTS AND 
SPECULUM FINDINGS 
S. No Speculum 
findings 
Pap smear results 
Normal 
n=55 
Abnormal 
n=45 
Total 
1 Normal 
Cervix 
40(81.6%) 9(18.4%) 
 
49 
2 Abnormal  
Cervix 
15(29.4%) 36(70.6%) 51 
 
70.6% of women with abnormal cervix had abnormal Pap smear.  
But only 18.4% women with normal cervix had abnormal Pap smear.  
 
       Chi-Square test: 
Value Df Sig 
25.465 1 .000 
 
P value <0.01; indicates that the relationship between Pap smear results and 
speculum findings is statistically significant. 
      
TABLE 13: 
DISTRIBUTION OF WOMEN ACCORDING TO CD4 COUNT 
 
 
 
 
 
 
 
 
 
 
       45% of women had CD4 count between200-500. 32% of 
       women had  CD4 count <200. Only 9% had CD4 count  
       above 700. 
           
 
 
 
 
S.No CD4 count Total no women 
n=100 
No of cases % 
1 
 
<200 32 32% 
2 
 
200-500 45 45% 
3 
 
500-700 14 14% 
4 
 
>700 9 9% 
TABLE 14: 
RELATIONSHIP BETWEEN PAP SMEAR FINDINGS  
AND CD4 COUNT 
S. No CD4 count Pap smear findings 
Normal     
n=55 
Abnormal    
n=45 
Total     
n=100 
1 <=200 17(53.1%) 15(46.9%) 32 
2 201-500 23(51.1%) 22(48.9%) 45 
3 501-700 7(50%) 7(50%) 14 
4 >700 8(88.9) 1(11.1%) 9 
 
48.9% of women with CD4 count between201-500 had abnormal Pap smear. Also 
46.9% of women with CD4 count<=200 had abnormal Pap smear. 
        Chi-Square Test: 
        
Value df Sig.  
1.670 2 .434 
 
P value >0.05; indicates that the relationship between Pap smear findings and CD4 
count is not statistically significant. Hence it is concluded that Pap smear 
abnormalities could occur irrespective of age group. 
 
 
TABLE 15: 
RELATIONSHIP BETWEEN CD4 COUNT AND EPITHELIAL 
ABNORMALITIES 
 
S. No 
 
CD4 count 
 
Total no of 
women           
n=100 
 
No of women with epithelial   
abnormalities 
LSIL   
n=3 
SCC    
n=2 
Total    
n=5 
 
1 <200 32(32%) 2(6.25%) - 2(6.25%)
2 200-500 45(45%) 1(2.22%) 2(4.44%) 3(6.66%)
3 500-700 14(14%) - - - 
4 >700 9(9%) - - - 
 
All women with epithelial abnormalities had CD count below 500. Two of them 
had SCC and one of them had LSIL. Mean CD4 count of women with epithelial 
abnormalities was 297.8 and mean CD4 count of women with SCC was 422.5.  
 
 
 
 
TABLE 16: 
COMPARISON OF VARIOUS ORGANISMS AND CD4 COUNT 
 
S. 
No 
 
CD4 
count 
 
Total no. of 
women 
No of women with organisms 
Candida 
n=7 
HSV 
n=4 
Tricho 
monas 
n=1 
Shift in flora  
n=8 
Total 
n=20 
1 
 
<200 32 
(32%) 
3 
(9.38%) 
1 
(3.13%) 
- 2 
(6.25%) 
 
 
6 
(18.76%)
2 
 
200-500 45 
(45%) 
2 
(4.44%) 
3 
(6.66%) 
- 3 
(6.66%) 
8 
(17.76%)
3 
 
500-700 14 
(14%) 
2 
(14.29%) 
- 1 
(7.14%) 
2 
(14.29%) 
5 
(35.72%)
4 
 
>700 9 
(9%) 
- - - 1 
(11.11%) 
1 
(11.11%)
 
 
Maximum incidence of organisms had CD4 count less than 500. 
Mean CD4 count of shift in flora - 387.57, candida - 385, herpes 
Virus -313. 
 
SUMMARY 
• The current study was conducted on 100 HIV infected women, attending 
Coimbatore medical college Hospital. 
• In the present study 65% women had gynecological problems. Vaginal 
discharge was the most common presenting symptom (51%). 
• Incidence of abnormal Pap smears was increased in HIV infected women. 
• In the present study 45% of women had abnormal Pap smear, which includes 
inflammation 14%, reactive atypia 6%, various organisms 20% and 
epithelial abnormalities 5%. 
• In the present study 8% women had shift in flora, 7% had candida and 4% 
had herpes virus. Maximum no of women with organisms had CD4 count 
less than 500.Mean CD4 count of shift in flora - 387.57, candida - 385, 
herpes virus-313.2.  
• Women with HIV and cervical cancer tend to be younger than HIV negative 
women with cervical cancer. 
• In the present study, maximum incidence of epithelial abnormalities were  
between age of 31-40 years . Both the cases of squamous cell carcinoma 
were under the age of 40 years. 
• Women infected with both HIV and high risk HPV had high risk of 
squamous intra epithelial lesions (SIL) than HIV non infected women. 
• In the present study one women had HPV related LSIL, whose CD4 count is 
131. 
• In the present study, maximum women with epithelial abnormalities had 
CD4 count between 200-500.Two of them had squamous cell carcinoma 
(SCC) and one of them had Low grade intra epithelial lesion (LSIL).  
• Mean CD4 count of women with epithelial abnormalities was 297.8 and 
mean CD4 count of women with SCC was 422.5 
 
 
 
 
   
                                      
CONCLUSION 
 
• Reproductive tract morbidities are common in HIV infected women. Hence, 
all HIV positive women must be screened periodically by Pap smear for 
evidence of genital tract involvement, so that they can be promptly and 
effectively treated.  
• Incidence of abnormal Pap smears is higher in HIV infected women. 
Exfoliative cervico vaginal cytology has been regarded as the gold standard 
for cervical screening programs. Pap smear is widely recognized as the most 
cost effective cancer screening test devised and serves as a model for 
screening of other malignancies. 
• The availability of cervical cytology to screen for cervical cancer often 
permits diagnosis at the pre invasive stage, when treatment can almost 
always prevent progression to invasive cancer.  
• For this reason, screening for cervical cancer is important in HIV infected 
women since the incidence of cervical intraepithelial neoplasia and cancer 
cervix are four to five times higher in HIV-positive women. 
 
 
• Also women with HIV and cervical cancer tend to be younger than HIV 
negative women with cervical cancer. 
• Hence our study conclude that all HIV positive women should  be regularly 
followed with Pap smear for evidence of lower genital tract neoplasia, 
regardless of age, CD4 count or viral load. 
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1 A0079 37 23 253    + + Middle 2nd std 
 
3yrs 7th day 
 
6 yrs No complaints NAD 
 
NILM 
2 A0200 28 25 234 + _ Middle 8th std 
 
3.5 yrs 20th day 2 Yrs No complaints Cervix NAD NILM 
3 A0216 45 23 578 + _ Low 8th std 3 yrs 7th day 12 Yrs Mild white 
Discharge 
 
Cervix NAD NILM 
4 A0252 43 25 560 + _ Middle 5th std 3.5 yrs 15th day 20 Yrs Mild white 
Discharge 
 
Erosion Cervix 
 
NILM/Shift in 
flora 
5 A0308 33 28 472 + _ Middle B.A 3.5 yrs 20thday 8 yrs White 
Discharge 
 
Erosion both 
cervical lips 
NILM / Reactive 
cellular changes 
6 A0412 43 20 32 + + Middle _ 4 yrs 20thday 17 yrs _ Erosion cervix NILM 
7 A0419 29 23 180      +       _ Middle 
 
10th std 
 
3.5 yrs 7th  day 
 
9yrs Dysuria Mild erosion 
cervix 
 
NILM 
 
8 A0482 37 24 227     +       _ High B Com 3 yrs 25th  day 
 
12 yrs _ NAD NILM 
9 A0512 28 21 224 + _ Middle 
 
10th std 
 
3.5 yrs 22nd day 4yrs _ NAD NILM 
 
10 A0533 40  16 310 + + Middle 8th  std 3yrs 10th day 19 yrs _ NAD NILM 
11 A0762 36 27 846 + _ Middle 7th std 2.5 yrs 10th day 7 yrs - NAD NILM 
12 A0800 37 24 227 + _ High BCom 2.5 yrs 25th day 12 yrs _ NAD  NILM 
13 A0828 35 20 179 _(2nd 
marri
age) 
+ Middle 
 
3rd std 2.5 yrs irregular _ Itching NAD NILM/ Reactive 
Cellular changes 
14 A0959 50 18 909 + + Low 8th std 2 yrs Post 
menopau
sal 
23 yrs Curdy 
discharge 
CX NAD NILM/ Atrophic 
smear 
15 A0979 42 30 529 +         + Middle 
 
 
_ 2.5 yrs irregular 14 yrs Mild white 
discharge P/V 
CX NAD NILM 
16 A0989 35 23 1056 + _ Middle 12th std 3 yrs 10th day 11yrs _ NAD  NILM 
17 A1007 47 19 31 + _ Low _ 2.5 yrs 15th day 23 yrs _ NAD  NILM 
18 A1014 36 20 1059 + _ Middle _ 1 yr 18th day _ Dysuria NAD NILM 
19 A1198 35 15 280 + _ Middle 5th std 2.5 yrs 8th day 14 yrs Thick white 
discharge  
Erosion  CX NLIM 
 
 
 
20 A1213 33 15 456 + _ Low _ 3 yrs 2 wks 13 yrs white discharge Erosion  CX NILM/Inflammati
on 
21 A1452 37 18 500 + _ Middle _ 2.5 yrs irregular _ - NAD NILM 
22 A1491 37 19 132 + _ Middle _ 2 yrs 7th day 21 yrs _ NAD NILM 
23 A1524 28 19 194 + _ Middle 5th std 2 yrs 20th day 3 yrs   curdy white 
discharge  
Erosion  CX NILM/ Candida 
24 A1555 29 19 167 + + Middle 5th std 1.5 yrs 7th day 8 yrs Thin white 
discharge  
NAD NILM 
25 A1630 40 18 572 + + Middle _ 1.5 yrs 15th day 20 yrs Itching Erosion  CX NILM 
26 A1736 30 20 311 _ + Middle 6th std 2 yrs 20th day 7 yrs Thin white 
discharge  
Erosion  CX  NILM 
27 A1737 35 19 273 + + Low 2nd std 1.5 yrs 20th day 14 yrs Thick curdy 
white discharge 
Erosion  CX NILM/Candida 
28 A1739 40 17 256 + + Low _ 2.5 yrs 10th day 23 yrs _ NAD NILM 
29 A1746 31 24 165 + _ Middle 12th std 2 yrs 17th day 6 yrs - NAD NILM 
30 A1791 48 17 247 + _ Middle _ 2.5 yrs 16th day 19 yrs Mild white 
discharge  
Erosion  CX NILM 
31 A1797 36  25 413 + _ Middle 3rd std 1.5 yrs  12th day 9 yrs _ NAD NILM 
32 A1834 39 19 21 _ + Low 5th std 1.5 yrs 6th day 16 yrs _ NAD NILM 
33 A1880 25 20 296 + _ Middle 10th std 6 
months 
25th day 4 yrs _ NAD NILM 
34 A1956 46 32 364 _ + Low _ 1.5 yrs Irregular 12 yrs Itching  Erosion  CX NILM 
35 A1976 29 19 64 + _ Middle 10th std 9 
months 
20th day 7 yrs Mild white 
discharge  
NAD NILM 
36 A2030 32 20 114 + + Middle - 1.5yrs irregular _ _ Erosion  CX NILM/ 
Inflammation 
37 A2139 35 17 648 + _ Middle 3rd std 1.5 yrs 15th day 14 yrs _ NAD NILM 
38 A2209 37 20 277 + _ Middle _ 7months 10th day 13 yrs white discharge NAD NILM 
39 A2343 40 18 229 _ + Middle _ 1.5 yrs 20th day 18 yrs Mild white 
discharge P/V 
Erosion CX NILM/ Reactive 
cellular changes 
40 A2388 35 25 176 + _ Middle 9th std 2 yrs 2 weeks 10 yrs white discharge 
P/V 
Erosion CX NILM/ Reactive 
cellular changes 
41 A2441 30 21 119 + _ Low 12th std 1 yr 15th day 6 yrs Mild white 
discharge P/V 
Erosion CX NILM/Inflammati
on 
42 A2466 50 23 83 + + Low  _ 1 yr Menopau
se 
20 yrs _ NAD Atrophic smear/ 
NILM 
43 A2487 27 20 70 + _ Middle _ 1 yr 15th day _  white 
discharge  
NAD NILM/shift in 
flora 
44 A2568 35 15 163 + + Middle _ 1 yr 15th day 4yrs _ _ NILM 
45 A2653 33 27 203 + _ Low 8th std 10mont
hs 
25th day 2 yrs white discharge Erosion CX NILM/shift in 
flora 
46 A2684 40 35 480 + + Low - 10mont
hs 
25th day 7 yrs white discharge 
P/V 
Erosion CX NILM/shift in 
flora  
47 A2743 29 27 161 + _ Middle 12th std 10 
months 
15th day 7mont
hs 
- NAD NILM 
48 A2747 35 21 194 _ + Middle  2nd  
std 
5months 15th day 6 yrs white discharge 
P/V 
Erosion CX NILM/ Candida 
49 A2835 42 20 131 + _ Low _ 8months Irregular 9 yrs White 
discharge P/V 
 Multiple 
Venereal warts 
 
LSIL/ HPV 
related 
 
50 A2897 42 19 132 _ + Middle _ 10 
months 
10th day 25 yrs - NAD NILM/ shift in 
flora  
51 A2919 48 20 187 + _ Low 
 
_ 1.5 yrs menopau
se 
_ _ CX- NAD NLIM/ Atrophic 
smear 
52 A2977 32 15 215 + + Middle _ 6months 7th day 15 yrs _ NAD NILM/shift in 
flora  
53 A3023 22 19 35 + + Middle 10th std 6months Irregular  1yr Dysuria NAD NILM/Inflammati
on 
54 A3030 31 16 191 + _ Low 4th std 6months 8th day 5 yrs _ NAD NILM 
55 A3034 37 18 54 + _ Middle 10th std 1 year 18th day 7 yrs _ Erosion Cx NILM/candida 
56 A3046 42 18 989 + _ Middle - 6months 8th day 15 yrs mild white 
discharge P/V 
Erosion Cx NILM/shift in 
flora  
57 A3083 30 17 237 + _ Low 8th std 5months 10th day 8 yrs mild white 
discharge P/V 
Erosion Cx  NILM 
58 A3149 44 15 151 + _ Middle        _ 4months 7th day 20 yrs mild white 
discharge P/V 
Erosion Cx NILM 
59 A3164 28 17 272 + _ low 9th std 6months 25th day 9 yrs mild white 
discharge P/V 
Erosion Cx  NILM/ 
Inflammation 
60 A3200 35 24 175 + _ Middle _ 4months 7th day 12 yrs mild white 
discharge P/V 
Erosion Cx NILM 
61 A3220 34 17 254 _ + Middle 
(CSW) 
8th Std 4months 10th Day 10 yrs Multiple small 
ulcers-vulva  
Erosion Cx NILM/Herpes 
simplex virus 
62 A3246 38 22 259 + + Middle 8th std 2months 11th Day 10 Yrs mild white 
discharge P/V 
Erosion Cx NILM/ 
Inflammation 
63 A3256 28 17 251 + _ Middle 3rd std 2months 20th Day 13 Yrs _ NAD NILM 
64 A3271 30 18 26 + _ Middle 4th std 2months irregular 9 Yrs mild white 
discharge P/V 
Erosion Cx NILM/ Reactive 
cellular changes 
65 A3312 22 19 333 + + Low 7th std 1 month 4th day  10Yrs Profuse foul 
smelling 
discharge P/V 
Erosion CX NILM/ 
Inflammation 
66 A3315 35 16 224 + _ Low 
 
_ 1 month 17th Day 12 yrs _ NAD NILM 
67 A3346 34 19 265 + _ Middle 8th std 1 month 8th day _ mild white 
discharge P/V 
Erosion Cx Cu-
T insitu 
NILM/ 
Inflammation 
68 A3392 28 23 94 + _ Middle  BSC 15 days irregular 4 Yrs Ulcers over 
labia. 
Erosion Cx NILM/Herpes 
simplex virus 
69 A3404 37 18 431 - + Middle 5th std 15 days 20th Day 18 Yrs Mild white 
discharge P/V 
Erosion Cx LSIL 
70 S0344 39 18 344 + _ Middle 5th std _ 20th Day 12 Yrs Mild white 
discharge P/V 
Erosion Cx NILM 
71 S1041 24 19 412 + _ Middle 10th std _ 20th Day 1.5 
yrs 
- - NILM 
72 S1066 31 23 827 + _ Middle 8th std _ 10th day 7 Yrs white discharge Erosion Cx NILM 
73 S1076 23 19 313 + + Middle 8th Std _ 25th Day 5 Yrs Vesicles over 
genitalia 
Erosion Cx NILM/Herpes 
simplex virus 
74 S1256 22 20 792 + _ Middle 6th std _ 25th Day 2 Yrs white discharge Erosion Cx  NILM 
 
75 S1752 31 21 315 + + Middle 10th std _ 20th Day 10 Yrs Curdy white 
discharge P/V 
Erosion Cx NILM/ 
Inflammation 
 
76 S2466 38 19 576 + _ Middle 5th std _ 12th Day  8Yrs Greenish 
discharge P/V 
Erosion Cx NILM/ 
Trichomonas 
vaginalis 
77 S2606 30 25 630 + _ Middle 12th std _ 12th Day 8mont
hs 
white discharge 
P/V 
Erosion Cx NILM 
78 S2698 20 17 592 + _ Middle 10th std _ 25th Day _ Ulcers over 
genitalia 
Erosion Cx NILM/Herpes 
simplex virus 
79 S2913 37 19 277 + + Middle 5th std _ 14th Day 13 Yrs _ NAD NILM 
80 S3653 23 17 272 + +2nd 
marriage 
Middle 10th std _ 25th Day 7 Yrs white discharge 
P/V 
Erosion Cx NILM/Reactive 
cellular changes 
81 S4897 45 19 838 + + Middle _ _ 20th Day 24 Yrs white discharge Erosion Cx NILM 
82 S4395 28 22 544 + _ Middle 12th std _ 2 weeks 5 Yrs white discharge 
P/V 
NAD NILM/ Shift  in 
flora 
83 S5183 24 21 679 + _ Middle 10th std _ 7thday 1 Yr white discharge 
P/V 
Erosion, curdy  
white discharge 
NILM/Candida 
84 S5268 26 18 529 + _ Middle 8th std _ 7th Day 10 Yr white discharge 
P/V 
Erosion Cx NILM 
85 S5702 43 19 628 + + Low 2nd Std _ 10th day 15 Yrs white discharge 
P/V  
Erosion Cx NILM/Candida 
86 S5728 31 22 185 + _ Middle 12th std _ 7th Day 8 yrs - - NILM 
87 S5830 35 19 396 + _ Middle 2nd std _ irregular 10 Yrs Irregular 
bleeding P/V 
Ulcerative 
growth CX, 
bleed on touch 
SCC 
88 S5873 35 15 472 + _ Middle 4th std _ 10th Day 10 Yrs white discharge Erosion Cx NILM/ 
Inflammation 
89 S6043 39 23 449 + _ Middle 3rd std _ irregular 10 Yrs excessive white 
discharge P/V 
 Bleed on touch SCC 
90 S6150 27 21 499 + _ Middle 9th std _ 10th day 9 Yrs white discharge 
P/V 
NAD NILM/ 
Inflammation 
91 S6180 33 20 342 + + Middle 8th std _ 7th Day 2 Yrs White 
discharge P/V 
NAD NILM/Candida 
92 S6413 30 27 432 + _ Middle 8th std _ 2 weeks 2 Yrs _ NAD NILM 
93 S6904 27 22 562 + _ Middle 5th std _ ANC-
5MA 
_ White 
discharge P/V 
NAD NILM/ 
Inflammation 
    LMP-Last menstrual period                                                            LCB-Last child birth 
    NAD – No abnormality detected                                                    S.E status- Socio economic status                                                                                              
    NILM  - Negative for Intra epithelial lesion or Malignancy          LSIL- Low grade squamous intraepithelial lesion    
    SCC  -  Squamous cell carcinoma                                                   
94 S6905 35 21 468 + _ Middle  5th std _ 14th Day  10 Yrs White 
discharge P/V 
NAD NILM/ 
Inflammation 
95 S6933 36 19 202 + _ Middle 2nd std _ 25th Day 14 yrs - NAD NILM 
96 S6977 29 17 565 + _ low 8th std _ 20th Day 2.5 
Yrs 
- NAD NILM 
97 S6994 40 25 122 + + low _ _ irregular _ _ NAD NILM 
98 S7052 45 19 768 + _ Middle 2nd std - 14th day 12 yrs _ NAD NILM 
99 S7061 32 18 82 + + low 5th std _ 14th day 10 Yrs Excessive 
white discharge 
Erosion CX LSIL 
100 S7082 34 19 120 
 
+ _ low 8th std  10th day 11 yrs Mild white 
discharge P/V 
Erosion CX 
 
NILM/ 
Inflammation 
PAPANICOLAOU STAINING PROCEDURE 
1. Slides were transferred directly from fixative, without drying, to       
80% alcohol and bring down through 70 and 50% alcohols to 
water. 
2. Stained in Harris’ hematoxylin for 4 minutes. 
3. Rinsed briefly in water. (All rinsing was gentle) 
4. Dipped in 0.25% HCl in alcohol about six times. 
5. Placed in running tape water for 6 minutes. 
6. Rinsed in distilled water & run through 50%, 70%, 80% to 95% 
alcohol. 
7. Stained in OG 6 for 2 to 4 minutes. 
8. Rinsed in two changes of 95% alcohol. 
9. Stained in EA 36 for 2 to 4 minutes. 
10. Rinsed in three changes of 95% alcohol. 
11. Dehydrated in absolute alcohol, followed by equal parts of      
absolute alcohol and xylol, cleared in xylol and mounted. 
 
 
 
PROFORMA 
1)  Name   
2)  Age    
3)  Sex              
4)  IP\OP NO   
5)  HIV status   
6)  Education   
7)  Occupation   
8)  Age at menarche   
9) Age at marriage         
10)  Menstrual history                  
11)  Sexual history, H/O extra marital contact   
12)  Parity 
13)  Last child birth  
14)  Excessive discharge Per Vaginum 
      (Nature, colour , odour and consistency ) 
15)  Bleeding Per Vaginum 
16)  Post coital bleeding 
17)  Pain abdomen, low back ache 
18)  Bladder and Bowel habits 
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